Advertisement
News
Advertisement

Verastem losses widen in Q3 post R&D ramp up

Tue, 11/13/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Verastem Inc., (NASDAQ: VSTM), a biotech company focused on cancer stem cells, reported that its loss widened in the third quarter due to a ramping up of research and development costs.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading